| Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to veligrotug (“veli”), the company's lead anti-insulin-like growth factor-1 receptor (IGF-1R) drug candidate for the treatment of TED. Breakthrough Therapy D. |
businesswire.com |
2025-05-07 20:15:00 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates |
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.79 per share a year ago. |
zacks.com |
2025-05-06 13:15:50 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2025. “We continue to execute across the portfolio as we work towards submitting the veligrotug BLA in the second half of 2025, advancing our VRDN-003 subcutaneous clinical tri. |
businesswire.com |
2025-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company's common stock to 13 new employees (t. |
businesswire.com |
2025-05-02 11:00:00 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement. |
businesswire.com |
2025-04-07 11:00:00 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window |
Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive and Thrive-2 trials bolster confidence, with VRDN-001 demonstrating rapid response and consistent efficacy in both active and chronic TED. Financially stable with a cash runway into 2027, Viridian is well-positioned for FDA approval, expected to be a significant catalyst for the stock. |
seekingalpha.com |
2025-03-02 09:36:54 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates |
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.35 per share a year ago. |
zacks.com |
2025-02-27 11:25:34 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 527,750 shares of the company's common stock to 15 new employees (the “Inducem. |
businesswire.com |
2025-02-06 18:01:00 |
Czytaj oryginał (ang.) |
| Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) |
Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy. |
seekingalpha.com |
2024-12-19 12:34:33 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation |
Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to Tepezza with statistically significant effects on diplopia response and diplopia resolution. Veligrotug's results also provide clinical de-risking for next-generation, subcutaneously administered candidate VRDN-003, which I expect to be the key long-term growth driver for the TED franchise. |
seekingalpha.com |
2024-12-18 12:56:02 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) |
Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved the chances of FDA approval for the company's lead candidate in 2026. Even after the rally in VRDN stock on Monday, the stock remains undervalued given its potential market. The company also has a large cash balance. |
seekingalpha.com |
2024-12-17 14:41:33 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease |
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease appeared first on Investor's Business Daily. |
investors.com |
2024-12-16 11:28:42 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics' eye disorder drug meets late-stage study goal |
Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study. |
reuters.com |
2024-12-16 09:10:18 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). TED is an autoimmune condition characterized. |
businesswire.com |
2024-12-16 09:00:00 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under “Events and. |
businesswire.com |
2024-12-13 20:00:00 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 391,500 shares of the company's common stock to 10 new employees (the “Inducem. |
businesswire.com |
2024-12-04 18:01:00 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates |
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago. |
zacks.com |
2024-11-12 11:26:09 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics' Superior Prospects Make It A Buy |
Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 achieved significant efficacy in the Thrive trial, meeting all primary and secondary endpoints with strong proptosis and diplopia resolution rates, and was well-tolerated. Financially, Viridian has a market cap of $1.87bn and a cash runway of 9–10 quarters, with a potential annual revenue of $8bn if successful. |
seekingalpha.com |
2024-10-23 20:02:11 |
Czytaj oryginał (ang.) |
| 3 Small Biotech Stocks With The 'Big Mo' Right Now |
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below. |
seekingalpha.com |
2024-09-19 16:54:05 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock |
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering price. |
businesswire.com |
2024-09-12 03:25:00 |
Czytaj oryginał (ang.) |
| VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints |
The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints. |
zacks.com |
2024-09-11 16:30:29 |
Czytaj oryginał (ang.) |
| Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way |
Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for THRIVE-2 study, using veligrotug for the treatment of patients with chronic thyroid eye disease, expected end of 2024. It is expected that the 7 major thyroid eye disease markets will reach $4.13 billion by 2034. |
seekingalpha.com |
2024-09-10 21:09:37 |
Czytaj oryginał (ang.) |
| Biotech Stock Scores Big Win, Squeezes Shorts |
Viridian Therapeutics Inc (NASDAQ:VRDN) stock is up 11.1% to trade at $15.75 today, and earlier traded as high as $16.35, after the biotech company's eye disorder treatment met the main goal of a late-stage study. |
schaeffersresearch.com |
2024-09-10 14:58:42 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study |
Viridian Therapeutics said on Tuesday its experimental drug to treat patients with thyroid eye disease significantly reduced bulging of the eye in a late-stage study. |
reuters.com |
2024-09-10 11:18:02 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates |
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.27 per share a year ago. |
zacks.com |
2024-08-08 14:25:58 |
Czytaj oryginał (ang.) |
| 3 Biotech Names With Potential Catalysts By Year End |
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024. |
seekingalpha.com |
2024-07-29 19:32:50 |
Czytaj oryginał (ang.) |
| Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength? |
Viridian Therapeutics (VRDN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-07-17 12:05:44 |
Czytaj oryginał (ang.) |
| 3 Small-Cap Stocks With Explosive 2X Growth Potential |
Small-cap stocks, typically valued between $300 million and $2 billion, often promise notable growth potential and superior long-term returns. Now, with interest rate cuts on the horizon, investors are speculating which high-growth small-cap stocks may thrive. |
investorplace.com |
2024-07-08 14:38:54 |
Czytaj oryginał (ang.) |